Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06008860 · ClinicalTrials.gov registry record · Phase 4
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
A Phase 4 study of COVID-19, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 280
- Enrollment target
- 1
- Study location
NCT06008860 is a Phase 4 study of COVID-19 that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 280 participants, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06008860, a Phase 4 study of COVID-19, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 280 participants
- Enrollment target
- 1
- Study location
Study Summary
The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the University of Chicago.
Conditions Studied
Interventions
- DRUG Experimental: Primary Cohort
- OTHER Placebo Comparator: Primary Cohort - Placebo
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06008860
The ClinicalTrials.gov registry entry for NCT06008860 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Experimental: Primary Cohort is the first listed.
NCT06008860 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06008860 about?
NCT06008860 is a clinical study titled "A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection". The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the University of Chicago.
What is the current status of trial NCT06008860?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 280 participants. The study started on 2023-07-01. Estimated completion is 2026-12.
What conditions does trial NCT06008860 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT06008860?
The interventions under investigation include: Experimental: Primary Cohort (DRUG), Placebo Comparator: Primary Cohort - Placebo (OTHER).
Who is sponsoring clinical trial NCT06008860?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06008860 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
RECRUITING · Phase 4
-
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
COVID-19 Reactogenicity
ACTIVE NOT RECRUITING · Phase 4
-
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
ACTIVE NOT RECRUITING · Phase 4
-
Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.